The association of serum galectin-3 and pre-dialysis blood pressure in hemodialysis patients and its prognostic evaluation of cardiovascular events

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200061988

Enrollment

Unknown

Registered

2022-07-15

Start date

2022-07-15

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: From July 2022 to June 2023, the patients who underwent maintenance hemodialysis in our hospital and were 18-90 years old.

Exclusion criteria

Exclusion criteria: Atrial fibrillation, ejection fraction < 50%, moderate to severe valvular disease, pericardial disease, restrictive cardiomyopathy, and patients whose blood pressure is still greater than 180/110 mmHg after treatment with three or more antihypertensive drugs during the dialysis interval.

Design outcomes

Primary

Measure	Time frame
Galectin 3;Nitric oxide;Endothelin 1;	—

Countries

China

Contacts

Public ContactLiqiong Jiang

Suzhou Hospital Affiliated to Nanjing Medical University

98qiong2008@163.com+86 13451974998

Outcome results